ArticleFrontiers in oncology2018
A Meta-Analysis of Vascular Endothelial Growth Factor for Nasopharyngeal Cancer Prognosis.
Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2021Pooled it
- Serum lactate dehydrogenase and vascular endothelial growth factor A level as a predictor of treatment response in locally advanced-stage World Health Organisation type 3 nasopharyngeal carcinoma.Contemporary oncology (Poznan, Poland) · 2026Article
- Dynamic Evolution of the Tumor Immune Microenvironment in Malignant Tumors and Emerging Therapeutic Paradigms.MedComm · 2025Review
- Exploring the Relationship Between YAP (Yes-Associated Protein) and VEGF-A with Distant Metastasis in Nasopharyngeal Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2024Observational
- The plasma EBV DNA load with IL-6 and VEGF levels as predictive and prognostic biomarker in nasopharyngeal carcinoma.Virology journal · 2024Article
- Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies.Frontiers in oncology · 2024Review
- Interactive role of miR-29, miR-93, miR-205, and VEGF in salivary adenoid cystic carcinoma.Clinical and experimental dental research · 2023Article
- Prognostic Biomarkers for Survival in Nasopharyngeal Carcinoma: A Systematic Review of the Literature.Cancers · 2022Review
- Nasopharyngeal Carcinoma and Its Microenvironment: Past, Current, and Future Perspectives.Frontiers in oncology · 2022Review
- Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment.BMC cancer · 2021Article
- Association Between VEGF Expression and Diffusion Weighted Imaging in Several Tumors-A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2019Article
- AMP-activated protein kinase α1 serves a carcinogenic role via regulation of vascular endothelial growth factor expression in patients with non-small cell lung cancer.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.